TTrialPathMatch Me to Trials
← Back to trials
RecruitingPrimary Membranous Nephropathy

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Eligible age

18–80 yrs

Accepts

All genders

Locations

19 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Sponsor: Vertex Pharmaceuticals Incorporated

Where it's recruiting

Alabama

Montgomery

Arizona

Surprise

California

Los Angeles · Sacramento · Tarzana

Colorado

Arvada

Florida

Miami · Orlando · Winter Park

Georgia

Columbus · Lawrenceville

Idaho

Boise

Illinois

Hinsdale

Indiana

Indianapolis

Louisiana

Shreveport

Missouri

Roseville

Source: ClinicalTrials.gov · NCT07204275 · last updated 2026-11-18

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Pa · TrialPath